Experimental and computational analysis of polyglutamine-mediated cytotoxicity

PLoS Computational Biology

Volumn 6, Issue 9, 2010, Pages

  Tang, Matthew Y ^a,b   Proctor, Carole J ^c   Woulfe, John ^a,b   Gray, Douglas A ^a,b,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CYTOTOXICITY; ENZYMES; NEURODEGENERATIVE DISEASES; STOCHASTIC MODELS; STOCHASTIC SYSTEMS;

CAUSATIVE AGENTS; COMPUTATIONAL ANALYSIS; COMPUTER MODELS; EXPERIMENTAL ANALYSIS; INCLUSION BODIES; POLYGLUTAMINE; POLYGLUTAMINE (POLYQ); PROTEASOMES; REACTIVE OXYGEN SPECIES; STOCHASTICS;

CHEMICAL ACTIVATION;

6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; HUNTINGTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYGLUTAMINE; PROTEASOME; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL DEATH; CELL INCLUSION; CELL STRESS; CELL VIABILITY; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; REPORTER GENE; STOCHASTIC MODEL;

EID: 78049415823     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000944     Document Type: Article

References (37)

1. Lowe J, Mayer J, Landon M, Layfield R (2001) Ubiquitin and the molecular pathology of neurodegenerative diseases. Adv Exp Med Biol 487: 169-186.
2. Gray DA, Tsirigotis M, Woulfe J (2003) Ubiquitin, proteasomes, and the aging brain. Sci Aging Knowledge Environ 2003: RE6.
3. Bedford L, Hay D, Devoy A, Paine S, Powe DG, et al. (2008) Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 28: 8189-8198.
4. Mitra S, Tsvetkov AS, Finkbeiner S (2009) Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease. J Biol Chem 284: 4398-4403.
5. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431: 805-810.
6. Woulfe JM (2007) Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress. Neuropathol Appl Neurobiol 33: 2-42.
7. Ross CA (1997) Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19: 1147-1150.
8. Firdaus WJ, Wyttenbach A, Giuliano P, Kretz-Remy C, Currie RW, et al. (2006) Huntingtin inclusion bodies are iron-dependent centers of oxidative events. FEBS J 273: 5428-5441.
9. Tsirigotis M, Baldwin RM, Tang MY, Lorimer IA, Gray DA (2008) Activation of p38MAPK contributes to expanded polyglutamine-induced cytotoxicity. PLoS One 3: e2130.
10. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitinproteasome system by protein aggregation. Science 292: 1552-1555.
11. Proctor CJ, Tsirigotis M, Gray DA (2007) An in silico model of the ubiquitinproteasome system that incorporates normal homeostasis and age-related decline. BMC Syst Biol 1: 17.
12. Ding Q, Dimayuga E, Keller JN (2006) Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS. Antioxid Redox Signal 8: 163-172.
13. Fernandes AF, Bian Q, Jiang JK, Thomas CJ, Taylor A, et al. (2009) Proteasome inactivation promotes p38 mitogen-activated protein kinase-dependent phosphatidylinositol 3-kinase activation and increases interleukin-8 production in retinal pigment epithelial cells. Mol Biol Cell 20: 3690-3699.
14. Ho AK, McNeil L, Terriff D, Price DM, Chik CL (2005) Role of protein turnover in the activation of p38 mitogen-activated protein kinase in rat pinealocytes. Biochem Pharmacol 70: 1840-1850.
15. Proctor CJ, Gray DA (2008) Explaining oscillations and variability in the p53- Mdm2 system. BMC Syst Biol 2: 75.
16. Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP, et al. (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet 11: 1137-1151.
17. Passos JF, Nelson G, Wang C, Richter T, Simillion C, et al. (2010) Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol 6: 347.
18. Sullivan PG, Dragicevic NB, Deng JH, Bai Y, Dimayuga E, et al. (2004) Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem 279: 20699-20707.
19. Giuliano P, De Cristofaro T, Affaitati A, Pizzulo GM, Feliciello A, et al. (2003) DNA damage induced by polyglutamine-expanded proteins. Hum Mol Genet 12: 2301-2309.
20. Illuzzi J, Yerkes S, Parekh-Olmedo H, Kmiec EB (2009) DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates. J Neurosci Res 87: 733-747.
21. Webber JL, Tooze SA (2010) Coordinated regulation of autophagy by p38alpha MAPK through mAtg9 and p38IP. EMBO J 29: 27-40.
22. Ding Q, Dimayuga E, Martin S, Bruce-Keller AJ, Nukala V, et al. (2003) Characterization of chronic low-level proteasome inhibition on neural homeostasis. J Neurochem 86: 489-497.
23. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, et al. (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17: 170-178.
24. Ortega Z, Diaz-Hernandez M, Maynard CJ, Hernandez F, Dantuma NP, et al. (2010) Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci 30: 3675-3688.
25. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, et al. (2003) The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 19: 524-531.
26. Wilkinson D (2006) Stochastic Modelling for Systems Biology Chapman & Hall/ CRC Press.
27. Gillespie DT (1977) Exact stochastic simulation of coupled chemical reactions. J Phys Chem 31: 2340-2361.
28. Gillespie CS, Wilkinson DJ, Proctor CJ, Shanley DP, Boys RJ, et al. (2006) Tools for the SBML Community. Bioinformatics 22: 628-629.
29. Kirkwood TB, Boys RJ, Gillespie CS, Proctor CJ, Shanley DP, et al. (2003) Towards an e-biology of ageing: integrating theory and data. Nat Rev Mol Cell Biol 4: 243-249.
30. Le Novere N, Bornstein B, Broicher A, Courtot M, Donizelli M, et al. (2006) BioModels Database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems. Nucleic Acids Res 34: D689-691.
31. Turnbull VJ, Storey E, Tarlac V, Walsh R, Stefani D, et al. (2004) Different ataxin-2 antibodies display different immunoreactive profiles. Brain Research 1027: 103-116.
32. Shoghi-Jadid K, Barrio JR, Kepe V, Wu H-M, Small GW, et al. (2005) Imaging b-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol 32: 337-351.
33. Diaz-Hernandez M, Moreno-Herrero F, Gomez-Ramos P, Moran MA, Ferrer I, et al. (2004) Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci 24: 9361-9371.
34. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, et al. (1999) The Ab peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616.
35. Olshina MA, Angley LM, Ramdzan YM, Tang J, Bailey MF, et al. Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool. J Biol Chem 285: 21807-21816.
36. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitinproteasome system by protein aggregation. Science 292: 1552-1555.
37. Garg T, Chang J (2004) 15-deoxy-delta 12, 14-Prostaglandin J2 prevents reactive oxygen species generation and mitochondrial membrane depolarization induced by oxidative stress. BMC Pharmacol 4: 6.